Sym004 is a recombinant IgG1 antibody product consisting of two antibodies against the epidermal growth factor receptor (EGFR). Sym004 is unique by inhibiting cancer cells by three separate and complimentary mechanisms of actions. Sym004 inhibits ligand binding, activation and subsequent downstream signalling of the EGF receptor. In addition, Sym004 induces rapid and efficient internalization and degradation of the EGF receptor and finally Sym004 induces immune-mediated killing of the cancer cells.

For a more detailed description, we refer to our article “Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy”.

Preclinical data reveal that Sym004 exhibits superior anti-cancer efficacy in vivo in a range of tumor xenograft models compared to marketed monoclonal anti-EGFR antibodies by a mechanism of action that is distinct from that of monoclonal antibodies.

Non clinical safety data indicate that Sym004 has a safety profile similar to marketed monoclonal antibodies.